• A significant rise in serum concentrations of aluminum was demonstrated in 23 patients prophylactically treated with the antacid magaldrate, whereas no increase in serum aluminium was observed in another 26 critically ill patients, in whom the use of antacids was avoided [1].

High impact information on Magaldrate

• The mean (SD) percentages of antacid retained in the stomach fit a linear model with a t1/2 of 86.6 (15.3) minutes for magaldrate and 52.3 (5.2) minutes for Maalox (p less than 0.01) [2].
• We studied the serum aluminum levels of 30 intensive care patients receiving six daily doses of magaldrate (Riopan) or aluminium hydroxide (Trigastril) [3].
• Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward [4].
• A randomized, placebo-controlled trial was performed to assess the effect of magaldrate (800 mg every 4 h) in reducing the rate of upper gastrointestinal tract bleeding among 100 consecutive patients with severe diseases admitted to a general hospital ward [4].
• These studies were carried out in simulated gastric juice and in buffer of pH 7.4 at 37 and 48 degrees C. Aluminum hydroxide, aluminum trisilicate, magnesium oxide, magnesium trisilicate, sodium bicarbonate, calcium carbonate, magaldrate and simethicone (2,4-dimethoxypolysiloxane) antacids were used in these studies [5].

Biological context of Magaldrate

• Coadministration of an antacid, magaldrate, or the antiulcer agent, sucralfate, had no effect on the bioavailability of etodolac in dogs, although with the latter, a significant reduction in Cmax was noted [6].
• Our data suggests the cytoprotective action of magaldrate on gastric mucosal cells which may be due to protection of gastric mucosa from lipid peroxidation [7].
• For the crushed tablet buffered with magaldrate (point estimates for AUC or Cmax: 0.88 or 1.12) bioequivalence with the intact tablet could not be formally demonstrated, although the lower confidence limit for AUC of 0.78 was only slightly below the lower limit of the equivalence range of 0.80 [8].

Anatomical context of Magaldrate

• Magaldrate is an effective and safe antacid to prevent gastrointestinal tract bleeding in such patients [4].
• Upper gastrointestinal tract bleeding occurred in 11 of 48 placebo-treated patients and in only 1 of 52 magaldrate-treated patients (p less than 0.01) [4].

Gene context of Magaldrate

• In vitro evaluation of magaldrate antacid efficacy in the presence of some drugs and its effect on their dissolution rates: Part I [9].

Analytical, diagnostic and therapeutic context of Magaldrate

• Differences between magaldrate and mixed gels are also apparent in pH-stat titrations in which magaldrate displays a biphasic response, contrasting to the two burst phases with an intervening lag phase observed for mixed gels [10].

References